文献速递炎症性肠病

奥扎尼莫德用于未接受过先进治疗的中重度溃疡性结肠炎患者

Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-05-08

基于True North研究及其开放标签延长期的事后分析,纳入616例未接受过先进治疗的溃疡性结肠炎患者。奥扎尼莫德在第4周症状应答率显著优于安慰剂(56% vs 39%),第10周和第52周所有疗效终点均显著改善;持续治疗者中91%维持临床应答至OLE第94周。安全性与该研究总人群一致。

要点

  • 未接受过先进治疗的患者中,奥扎尼莫德第4周症状应答率56% vs 安慰剂39%,差异显著。
  • 持续奥扎尼莫德治疗者91%维持临床应答至OLE第94周,74%达到内镜改善,57%达到黏膜愈合。
  • 第10周无临床应答者经延长诱导后,62%在OLE第10周达到症状应答。

核心结论

  • 奥扎尼莫德是未接受过先进治疗的溃疡性结肠炎患者有效、持久且耐受良好的口服治疗。

研究设计与样本

  • True North为随机、双盲、安慰剂对照3期试验,含10周诱导期和42周维持期,符合条件者可进入正在进行的开放标签延长期(OLE)。
  • 本分析纳入616例未接受过先进治疗的活动性疾病患者。

主要发现

  • 第2周时奥扎尼莫德组症状应答比例数值上高于安慰剂组(39% vs 29%,95%CI -0.1至18.8)。
  • 第4周时奥扎尼莫德组症状应答率显著高于安慰剂组(56% vs 39%,95%CI 6.3至26.3)。
  • 第10周和第52周,奥扎尼莫德组在所有疗效终点上均较安慰剂组显著改善(P < .05)。
  • 第52周进入OLE时处于临床应答的持续奥扎尼莫德治疗者中,91%维持临床应答至OLE第94周,74%达到内镜改善,57%达到黏膜愈合。
  • 第10周无临床应答的奥扎尼莫德治疗者接受OLE延长诱导后,62%在OLE第10周达到症状应答;未接受过先进治疗患者的安全性结局与True North总人群一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The pivotal phase 3 True North (TN) study demonstrated the efficacy and safety of ozanimod in patients with moderately to severely active ulcerative colitis. This analysis assessed ozanimod during TN and the ongoing open-label extension (OLE) in patients with active disease who were naive to advanced therapies (ATs). METHODS: TN was a randomized, double-blind, placebo-controlled trial consisting of 10-week induction period and 42-week maintenance period. Eligible patients could enter the OLE. Symptomatic efficacy was evaluated from induction through the OLE. Clinical, endoscopic, and mucosal outcomes were evaluated at the end of induction (Week [W] 10) and maintenance (W52) and at predefined OLE timepoints (OLE W46 and W94). Safety during TN was reported. RESULTS: This analysis included 616 AT-naive patients. Numerically greater proportions of patients receiving ozanimod than placebo achieved symptomatic response (39% vs 29%, 95% confidence interval, -0.1 to 18.8) by W2, with significant differences (56% vs 39%, 95% confidence interval, 6.3-26.3) achieved by W4. Patients receiving ozanimod showed significant improvements across efficacy outcomes versus placebo at W10 and W52 (P < .05, all endpoints). In patients on continuous ozanimod who entered the OLE in clinical response at W52, 91% maintained clinical response through OLE W94, and 74% achieved endoscopic improvement and 57% achieved mucosal healing at OLE W94. In ozanimod-treated patients without clinical response by W10 who received extended induction in the OLE, 62% achieved symptomatic response by OLE W10. Safety outcomes in AT-naive patients were consistent with the total TN population. CONCLUSIONS: Ozanimod is an effective, durable, and well-tolerated oral therapy for AT-naive ulcerative colitis patients. CLINICALTRIALS: gov, numbers NCT02435992 and NCT02531126.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sands BE, D'Haens G, Panaccione R, et al. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies. Clin Gastroenterol Hepatol. 2024. PMID: 38723981. doi:10.1016/j.cgh.2024.03.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。